utaa91
Cell therapyexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 18, 2025 (NCT06970951)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06982547 | Early Phase 1 (Phase 1) | Jun 30, 2025 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
| NCT06982534 | Early Phase 1 (Phase 1) | Jun 30, 2025 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
| NCT07001956 | Early Phase 1 (Phase 1) | May 30, 2025 | Huazhong University of Science and Technology |
| NCT07000682 | Early Phase 1 (Phase 1) | May 30, 2025 | Huazhong University of Science and Technology |
| NCT06970951 | Early Phase 1 (Phase 1) | May 18, 2025 | PersonGen BioTherapeutics (Suzhou) Co., Ltd., Soochow University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PersonGen BioTherapeutics (Suzhou) Co., Ltd. | For profit | 3 | 3 | 1 | 2025 |
| Huazhong University of Science and Technology | Academic/Hospital | 2 | 2 | 1 | 2025 |
| Soochow University | Academic/Hospital | 1 | 0 | 1 | 2025 |
3 organizations
Page 1 / 1